Arcadia Biosciences, Inc.
RKDA · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $0 | $0 | $0 | $0 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $0 | -$0 | -$0 | -$0 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | 13.3% | -40% | 9.4% | – |
| Gross Profit | $0 | $0 | $0 | -$0 |
| % Margin | 41.3% | 51.2% | 17.8% | -28.4% |
| EBITDA | -$0 | -$0 | -$0 | -$0 |
| % Margin | -148.6% | -128.7% | -198.8% | -408.7% |
| Net Income | -$0 | -$0 | -$0 | -$0 |
| % Margin | -139.5% | -313.9% | -207.3% | -216.2% |
| EPS Diluted | -5.16 | -11.3 | -26.05 | -30.33 |
| % Growth | 54.3% | 56.6% | 14.1% | – |
| Operating Cash Flow | -$0 | -$0 | -$0 | -$0 |
| Capital Expenditures | -$0 | -$0 | -$0 | -$0 |
| Free Cash Flow | -$0 | -$0 | -$0 | -$0 |